AZD-1208 is a Pim-1 kinase inhibitor that exhibits anticancer chemotherapeutic activity. In acute myelogenous leukemia (AML) cells, AZD-1208 induces cell cycle arrest and apoptosis, inhibiting phosphorylation of downstream targets such as Bcl-2, 4EBP1, p70S6K, and S6 and suppressing cell growth. In vivo, AZD-1208 inhibits growth of prostate tumor xenografts.
| Cas No. | 1204144-28-4 |
|---|---|
| Purity | ≥98% |
| Formula | C21H21N3O2S |
| Formula Wt. | 379.48 |
| IUPAC Name | (5E)-5-[[2-[(3R)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione |
| Solubility | DMSO 75 mg/mL warmed (197.63 mM) Water Insoluble Ethanol Insoluble |
| Appearance | Pale Yellow Powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Kirschner AN, Wang J, van der Meer R, et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst. 2014 Dec 13;107(2). PMID: 25505253.
Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13. PMID: 24363397.
